United States securities and exchange commission logo





                              October 3, 2022

       David Rosenberg
       Chairman and Co-Chief Executive Officer
       Ignyte Acquisition Corp.
       640 Fifth Avenue, 4th Floor
       New York, NY 10019

                                                        Re: Ignyte Acquisition
Corp.
                                                            Proxy Statement on
Schedule 14A
                                                            Filed September 23,
2022
                                                            File No. 001-39951

       Dear David Rosenberg:

             We have reviewed your filing and have the following comment. In
our comment, we
       may ask you to provide us with information so we may better understand
your disclosure.

              Please respond to this comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to this comment, we may have additional comments.

       Proxy Statement on Schedule 14A filed September 23, 2022

       General

   1.                                                   With a view toward
disclosure, please tell us whether your sponsor is, is controlled by, has
                                                        any members who are, or
has substantial ties with, a non-U.S. person. Please also tell us
                                                        whether anyone or any
entity associated with or otherwise involved in the transaction, is,
                                                        is controlled by, or
has substantial ties with a non-U.S. person. If so, please revise your
                                                        filing to include risk
factor disclosure that addresses how this fact could impact your
                                                        ability to complete
your initial business combination. For instance, discuss the risk to
                                                        investors that you may
not be able to complete an initial business combination with a
                                                        target company should
the transaction be subject to review by a U.S. government entity,
                                                        such as the Committee
on Foreign Investment in the United States (CFIUS), or ultimately
                                                        prohibited. Further,
disclose that the time necessary for government review of the
                                                        transaction or a
decision to prohibit the transaction could prevent you from completing an
                                                        initial business
combination and require you to liquidate. Disclose the consequences of
                                                        liquidation to
investors, such as the losses of the investment opportunity in a target
 David Rosenberg
Ignyte Acquisition Corp.
October 3, 2022
Page 2
      company, any price appreciation in the combined company, and the
warrants, which
      would expire worthless.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Please contact Daniel Crawford at 202-551-7767 or Alan Campbell at
202-551-4224 with
any questions.



                                                          Sincerely,
FirstName LastNameDavid Rosenberg
                                                          Division of
Corporation Finance
Comapany NameIgnyte Acquisition Corp.
                                                          Office of Life
Sciences
October 3, 2022 Page 2
cc:       Scott Cowan, Esq.
FirstName LastName